Why Is Retail Technology Company Diebold Nixdorf’s Stock Jumping Today?

Discover Diebold Nixdorf Inc's Q1 FY24 sales growth, surpassing analyst expectations. Banking revenue soared by 9.4%, while Retail revenue faced a slight decline. Despite a marginal drop in gross profit, operating income surged, indicating enhanced profitability. CEO Octavio Marquez emphasizes the company's solid start in 2024, focusing on expanding gross margin and free cash flow.

Retail technology company Diebold Nixdorf Inc (NYSE:DBD) reported first-quarter FY24 sales growth of 4.3% year-on-year to $895.40 million, beating the analyst consensus estimate of $875.65 million.

Banking revenue increased 9.4% to $648.8 million, and Retail revenue declined 7% to $246.6 million.

The gross profit fell 0.3% to $208.6 million and the gross margin contracted 110 basis points to 23.3%.

Operating income for the quarter was $23.8 million against a loss of $(2.1) million. Operating margin expanded 290 basis points to 2.7%.

EPS of $(0.39) missed the analyst consensus estimate of $0.23.

Adjusted EBITDA jumped 62.2% to $103.3 million with a margin of 11.5%. Diebold held $407.3 million in cash and equivalents as of March-end.

“We are off to a solid start in 2024. We reported strong results during the first quarter, showing good progress on our financial and operational priorities to expand gross margin and free cash flow. This resulted in another quarter of improved profitability and free cash flow conversion compared to the prior-year period,” said President and CEO Octavio Marquez.

Outlook: Diebold reaffirmed FY24 revenue guidance of low single-digit growth.

The company sees adjusted EBITDA of $410 million – $435 million and a free cash flow conversion of 25%.

Price Action: DBD shares are trading higher by 9.11% at $34.00 at the last check Thursday.

Total
0
Shares
Related Posts
Read More

EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder

Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD).

ALZN